We examined therapeutic in vitro and in vivo approaches using lentivirus-based packaging of small interfering RNAs (siRNAs) targeting the non-integrin laminin receptor mRNA for treatment and prevention of prion disorders. Transfection of N2aSc
Transmissible spongiform encephalopathies (TSEs) are fatal neurodegenerative disorders affecting animals and humans. TSEs are characterized by the accumulation of an 'abnormal' pathogenic isoform (PrP Sc ) of the host-encoded cellular prion protein (PrP c ) in the brain of affected individuals (Prusiner et al., 1998) . According to the 'protein-only' hypothesis, the conversion of PrP c to PrP Sc is the pivotal event in the aetiology of TSEs (Prusiner et al., 1990) . Since prion diseases are lethal disorders, great endeavours have been undertaken to develop an efficient anti-prion therapy (for reviews see Ludewigs et al., 2007; Trevitt & Collinge, 2006; Weissmann & Aguzzi, 2005) .
The 37/67 kDa laminin receptor (LRP/LR) was identified as the receptor for prions (Gauczynski et al., 2006 (Gauczynski et al., , 2001b and is localized on the cell surface, in the cytoplasm and the nucleus, respectively (for reviews see Gauczynski et al., 2001a; Ludewigs et al., 2007; Vana et al., 2007 , 2008 , Zuber et al., 2007a . Furthermore, LRP/LR colocalizes with PrP on the cell surface (Gauczynski et al., 2001b) and in the perinuclear compartment (Nikles et al., 2008) . LRP/LR binding to laminin, elastin and carbohydrates accounts for its fundamental role in cell adhesion, cell movement and growth (for review see Gauczynski et al., 2001a; Rieger et al., 1999) . LRP/LR plays an important role in the invasive and metastatic potential of neoplastic cells (Givant-Horwitz et al., 2005; Landowski et al., 1995) and tumour angiogenesis (Tanaka et al., 2000) (for reviews see Castronovo, 1993; Menard et al., 1997; Vana et al., 2008) . Blocking or downregulating LRP/LR hampers the invasive potential of tumorigenic fibrosarcoma cells, by blocking the laminin-1-LRP/LR interaction on the cell surface (Zuber et al., 2008b) . LRP/LR further supports maintenance of nuclear structures (Kinoshita et al., 1998) , supports the translation process in the cytosol (Auth & Brawerman, 1992) and plays a critical role in maintaining cell viability by preventing apoptosis (Susantad & Smith, 2008) . On the cell surface LRP/LR acts as a receptor for viruses such as adeno-associated virus (AAV), dengue virus and alphaviruses (for reviews see Ludewigs et al., 2007; Vana et al., 2007 Vana et al., , 2008 Zuber et al., 2007a) . However, the LRP/LR 3These authors contributed equally to this work.
polymorphism seems to be enigmatic. The 37 kDa LRP is thought to be the precursor of the 67 kDa high affinity laminin receptor. In mammalian cells, both LRP and LR are present in plasma membrane fractions (Gauczynski et al., 2001a) . In mouse brain both isoforms exist (Simoneau et al., 2003) . In adult rat brain the LR represents the major isoform, whereas LRP is expressed in the post-natal central nervous system (Baloui et al., 2004) . LRP is upregulated in spinal cord microglia after activation by a traumatic lesion or peripheral injury (Baloui et al., 2008) . The identification of LRP/LR as the receptor for prions conducts the idea of an alternative strategy for a TSE therapy. Application of either LRP-specific small interfering RNAs (siRNAs), the polyclonal anti-LRP antibody W3 (Leucht et al., 2003) as well as a trans-dominant-negative LRP mutant (Vana & Weiss, 2006) interferes with PrP Sc propagation in vitro. Passive immunotransfer of W3 into scrapie-infected mice significantly reduced the peripheral PrP Sc level concomitant with a prolongation of survival (Zuber et al., 2007b) . Delivery of single-chain (sc) Fv antibodies directed against LRP/LR into mice by either passive immunotransfer (Zuber et al., 2008a) or microinjection of recombinant AAV (Zuber et al., 2008c) both resulted in a significant reduction of peripheral PrP Sc propagation.
A series of chemical compounds have been identified as therapeutic agents efficiently interfering with PrP Sc propagation. Among these, only some are efficient both in vitro and in vivo (for review see Ludewigs et al., 2007) . Gene therapy approaches evolved due to possible side effects of drugs (e.g. toxicity, kidney damage, high blood pressure etc.) and the limitation of either passive or active immunization strategies.
RNA interference (RNAi) technology has been described as one of the most powerful systems to knock-down an endogenous gene at the post-transcriptional level (Tuschl et al., 1999) . siRNA-mediated gene transfer by lentiviral vectors leads to a long-lasting silencing effect due to an integration of lentiviral DNA into the genome of the target cells (Naldini et al., 1996a) .
In this study, human immunodeficiency virus (HIV)-derived vectors that enable the expression of short hairpin RNA (shRNA) directed against murine LRP mRNA were generated. To examine the efficiency of siRNA target sequences within the LRP mRNA ( Supplementary Fig. S1 available in JGV Online), transfections of siRNA-encoding plasmids (pENTR) were performed using chronically scrapie-infected mouse neuronal cells (N2aSc + ) ( Fig. 1 ). Cells were cultured in Dulbecco's modified Eagle's medium with GlutaMax-I (Gibco) containing 10 % fetal calf serum, 16 minimal essential medium non-essential amino acids, 100 U penicillin ml
21
, 100 mg streptomycin ml 21 and 0.5 mg geneticin ml 21 at 37 u C in 5% CO 2 . Posttransfection (72 h), cell lysates were subjected to + cells were subjected to SDS-PAGE following Western blotting. Cellular LRP/LR levels were detected using the single-chain anti-LRP antibody N3 (upper panel). As loading control anti-b-actin antibody (Sigma) was used (lower panel). PrP Sc detection was carried out in proteinase K-digested cell lysates using anti-PrP SAF83 antibody (middle panel). Molecular mass markers in kilodalton (kDa) are indicated on the left. (b) Quantitative analysis using the NIH Image software revealed reduced endogenous LRP levels by 50 % for pENTR siRNA-LRP 4-(P,0.005), 47 % for pENTR siRNA-LRP 7-(P,0.005) and 54 % for pENTR siRNA-LRP 9-(P,0.05) transfected cells, respectively, in comparison to pENTR siRNA-Lamin A/C-transfected cells (LRP level set to 100 %). PrP Sc levels were reduced by 50 % for pENTR siRNA-LRP 4-(P,0.05), 40 % for pENTR siRNA-LRP 7-(P,0.05) and 43 % for pENTR siRNA-LRP 9-(P,0.05) transfected cells, respectively, in comparison to pENTR siRNA-Lamin A/C-transfected cells (PrP Sc level set to 100 %). The results of three individual experiments are shown and expressed as percentages of control levels±SD.
SDS-PAGE and Western blotting. Employment of the anti-LRP single-chain antibody N3 predominantly recognizing the 37 kDa LRP form (Zuber et al., 2008a) and the PrPspecific SAF83 antibody revealed that both LRP and PrP Sc levels were significantly reduced, when using pENTR siRNA-LRP 4, 7 and 9 comparing these with the control pENTR siRNA-Lamin A/C (Fig. 1a, upper and middle panel). Quantitative analysis (for all quantitative analyses the Student's t test was used) of three independent experiments revealed a significant reduction of the LRP and PrP Sc content by 50 % with pENTR siRNA-LRP 4, by 47/40 % using pENTR siRNA-LRP 7 and by 54/43 % using pENTR siRNA-LRP 9, respectively (Fig. 1b) , confirming an important role for LRP in prion propagation.
Using the Block-it Lentiviral RNAi Expression System (Invitrogen), lentiviral RNAi vectors encoding siRNAs directed against the LRP mRNA were generated according to the manufacturer's instructions. After integration of lentiviral vector DNAs LVsiRNA-LRP 7 and 9 into the genome of mouse neuroblastoma cells (N2a) (data not shown), Western blot analysis of cell lysates revealed a significant LRP/LR downregulation when comparing N2a cells with integrated LVsiRNA-Lamin A/C DNA (data not shown).
To investigate the effect of the LRP-specific siRNAs in vivo, lentiviral particles [1610 4 transducing units (TU) per mouse] were microinjected via a stereotactic device into the cortex of 6-week-old anaesthetized C57BL/6 mice (four mice per group) using a Hamilton syringe connected with a 27-gauge needle with a flux of 1 ml min
. Cortex samples (10 % homogenates) were prepared 15 days postinjection, followed by Western blot analysis of the LRP/LR levels (Fig. 2a) . Quantitative analysis revealed a significant reduction of the cortical LR level by 62 and 82 %, respectively, after microinjection of lentiviral vectors LVsiRNA-LRP 7 and 9, respectively, compared with mice treated with LVsiRNA-Lamin A/C. Animals treated with LVsiRNA-LRP 4 showed a not significant reduction of the LR level by 45 % (P,0.5) (Fig. 2b) , suggesting a diminished effectiveness in vivo.
Due to the significant LRP-specific silencing effects of LVsiRNA-LRP 7 and 9, respectively, both lentiviral vectors were selected for further studies in scrapie-infected mice. Two weeks after microinjection of the lentiviral particles (2.1610 6 TU per mouse) into the hippocampus of the right hemisphere, mice were inoculated with 20 ml 1 % RML brain homogenate into the same brain region. To investigate whether lentiviral particles expressing siRNAs directed against LRP mRNA have the capacity to influence the etiopathology of prion diseases, mice were monitored for the occurrence of TSE-relevant symptoms (Sethi et al., 2002) (Fig. 3a) . Statistical evaluation using Kaplan-Meier survival curves demonstrated a significant prolongation of the pre-clinical phase in mice microinjected with LVsiRNA-LRP 7 (145±0 days, P,0.005) and LVsiRNA-LRP 9 (143±3 days, P,0.05), respectively, in comparison Fig. 2 . In vivo effect of lentiviral particles expressing siRNAs directed against the LRP mRNA. (a) Lentiviral particles encoding siRNAs targeting LRP mRNA were microinjected into the cortex of C57BL/6 mice. Cortex homogenates (10 %) were prepared 15 days post-injection and analysed by SDS-PAGE followed by Western blotting. Single-chain antibody scFv S18 (Zuber et al., 2008a) was used for LR detection (upper panel) and equally loaded protein amounts were verified with the anti-b-actin antibody (Sigma) (lower panel). Molecular mass markers in kilodalton (kDa) are indicated on the left. (b) Quantification of the Western blot signals revealed reduced LR levels for LVsiRNA-LRP 4-, LVsiRNA-LRP 7-and LVsiRNA-LRP 9-treated animals by 45 (P,0.5), 62 (P,0.05) and 82 % (P,0.005), respectively, in comparison to siRNA Lamin A/C-treated animals (LR level set to 100 %). Experiments were performed in triplicate (four animals per group) and results were expressed as percentages of control levels±SD. a5number of animals.
to mice microinjected with the control LVsiRNA-Lamin A/ C (139±0 days) (Fig. 3b, c) .
To analyse the protein levels, hippocampal samples were extracted 90 days post-scrapie inoculation, digested with 20 mg proteinase K ml 21 of total protein for 30 min at 37 u C following methanol precipitation and subjected to SDS-PAGE and Western blotting. Quantification of the data revealed a significant reduction of the endogenous LRP and PrP Sc levels by 36 and 41 %, respectively, using LVsiRNA-LRP 7 (Fig. 3d) . While intracerebral microinjection of LVsiRNA-LRP 9 resulted in a significant reduction of the LR level in the cortex of non-infected mice, the same lentiviral vector failed to significantly reduce the LRP level in scrapie-infected animals (Fig. 3d ), although the PrP Sc level was significantly reduced by 38 %. We hypothesize Fig. 3 . Analysis of scrapie-infected C57BL/6 mice after microinjection of lentiviral vectors expressing siRNAs directed against the LRP mRNA into the hippocampus. (a) Mice were microinjected with lentiviral particles 2 weeks prior to intracerebral inoculation with 1 % RML homogenate. The first group of mice was sacrificed 90 days post-scrapie-infection to analyse the LRP and PrP content, respectively. Remaining mice were monitored and sacrificed at the day when two of the TSE-relevant symptoms (Sethi et al., 2002) appeared over 3 days. The pre-clinical phase (incubation time) of the disease is defined as the time from the day of scrapie inoculation until the day where the first TSE-relevant symptom (Sethi et al., 2002) occurred, whereas survival is the time from the day the first symptom occurred until the day where two symptoms (Sethi et al., 2002) are manifested on 3 consecutive days. (b) Kaplan-Meier curve of 1 % RML-infected mice (seven animals per group) microinjected with LVsiRNA-LRP 7 (diamond), LVsiRNA-LRP 9 (square) and LVsiRNA-Lamin A/C (triangle), respectively. (c) Statistical evaluation of the pre-clinical phase, survival and life span in scrapie-infected mice after injection of lentiviral vectors LVsiRNA-LRP 7, 9 and Lamin A/C, respectively. Pre-clinical phase (incubation time) and survival are defined in (a). Life span is defined as pre-clinical phase plus survival. Days p.i.5days post-RML inoculation. (d) Western blot data of hippocampus homogenates (10 %) from scrapie-infected mice after injection of lentiviral vectors LVsiRNA-LRP 7, 9 and Lamin A/C, respectively, 90 days post-scrapie inoculation were quantified by NIH Image software. Antibodies scFv S18 (Zuber et al., 2008a) and SAF83 were used for LRP and PrP Sc detection, respectively. An anti-b-actin antibody (Sigma) was used for b-actin detection (control). LRP and PrP Sc levels of LVsiRNA-LRP 7 and LVsiRNA-LRP 9-treated mice were reduced by 36 (P,0.05)/41 % (P,0.05) and 12 (P,0.5)/38 % (P,0.05), respectively, in comparison to LVsiRNA-Lamin A/C-treated animals (LRP/PrP Sc levels were set to 100 %). Experiments were performed in triplicate (seven animals per group) and expressed as percentages of control levels±SD.
that due to the different distribution of LRP/LR isoforms in the brain (Baloui et al., 2004) , scFv S18 used for LRP/LR detection might preferentially recognize LR in the cortex and LRP in the hippocampus, respectively. Furthermore, it has been demonstrated that LRP levels in the brains of scrapie-infected hamsters are increased in comparison to uninfected animals (Rieger et al., 1997) . The silencing effect of lentiviral vectors expressing siRNAs directed against LRP mRNA might be weakened by so far unknown mechanisms in the cell enhancing LRP expression in response to a scrapie infection.
In the present study, we employed a lentiviral LRP-specific siRNA approach and demonstrated a downregulation of LRP/LR gene expression concomitant with a decrease of PrP Sc levels in both a scrapie cell culture and animal model, confirming an essential requirement of LRP/LR for prion propagation (Leucht et al., 2003) . In addition, in scrapieinfected mice injected with lentiviral vectors expressing LRP-specific siRNAs, a significant prolongation of the preclinical phase has been observed.
Thus, lentiviral-mediated siRNA delivery represents a promising therapeutic tool to specifically knock-down disease-relevant genes. The advantage of lentiviral vectors lies in their ability to transduce dividing cells such as embryonic stem cells (Pfeifer et al., 2006) , and nondividing and terminally differentiated cells such as neurons (Blomer et al., 1997; Naldini et al., 1996b) . Recently, lentiviral gene transfer of PrP, containing dominantnegative mutations, was performed and resulted in an inhibition of PrP Sc formation in chronically scrapieinfected neuronal cells (Crozet et al., 2004) . Furthermore, lentivector-mediated RNAi was used to generate chimeric mice that express lower PrP levels depending on the degree of chimerism. In highly chimeric mice, survival was significantly prolonged after scrapie infection (Pfeifer et al., 2006) . These data show that the application of the RNAi technology is a highly effective therapeutic approach against various neurological diseases.
Very recently, we developed an AAV-based gene delivery system targeting LRP/LR by transferring anti-LRP/LR single-chain antibody into scrapie-infected mice (Zuber et al., 2008c) . This approach resulted in a significant reduction of peripheral PrP Sc propagation without a significant prolongation of incubation times and survival (Zuber et al., 2008c) . In contrast, the lentiviral siRNA delivery system presented here resulted in a significant prolongation of the pre-clinical phase in scrapie-infected mice, pointing towards an alternative therapeutic tool for the treatment of prion disorders.
